Acute Myeloid Leukemia with or without NPM1 Mutation, Relapsed or Refractory High-Risk Myelodysplastic Syndrome, Relapsed / Refractory Metastatic or Advanced Solid Tumors
Conditions
Brief summary
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Detailed description
Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study
Interventions
Sponsors
Ryvu Therapeutics S.A.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study | — |
Countries
France, Italy, Poland, Spain
Outcome results
None listed